Brain Tumours are abnormal growths of cells within the brain or, in broader usage, the central nervous system, and they include both benign and malignant tumours. The term therefore does not automatically mean cancer. Brain tumours are classified according to their cell of origin, molecular characteristics, anatomical location, grade and other pathological features. Some arise from cells intrinsic to the central nervous system, while others represent metastases from cancers originating elsewhere in the body. The National Cancer Institute notes that brain and spinal cord tumours can be benign or malignant and that classification depends on the cell and location from which the tumour originates.
Primary Brain Tumours include several biologically distinct groups. Gliomas arise from glial or glial-lineage cells and include astrocytic and oligodendroglial tumours, while other primary tumours include meningiomas, ependymomas, medulloblastomas, schwannomas and tumours arising in other specialised structures. Modern classification increasingly uses molecular features alongside microscopic appearance. For example, particular mutations or chromosomal alterations can define biologically meaningful tumour categories and influence prognosis and treatment. Childhood and adult brain tumours differ in their distribution, biology and treatment, so age is an important component of classification.
Symptoms of Brain Tumours depend strongly on anatomical location, size, growth rate and effects on surrounding tissue or cerebrospinal-fluid circulation. Possible manifestations include headache, seizures, weakness, sensory disturbance, balance problems, visual changes, speech or language difficulties, cognitive changes and altered behaviour. Some tumours are discovered incidentally before producing symptoms, while others cause progressive neurological deficits. Headache alone is common and usually has non-tumour causes, so it should not be interpreted as evidence of a brain tumour without considering its pattern and associated findings. New seizures, progressive neurological deficits or significant changes in cognition can warrant urgent medical evaluation.
Diagnosis usually begins with neurological and general clinical assessment followed by brain imaging when indicated. MRI is commonly central to characterising brain tumours because it provides detailed anatomical and tissue information, while CT can be important in urgent situations and for certain structural assessments. Imaging can demonstrate tumour location, size, enhancement patterns, oedema, mass effect and other features, but imaging alone may not always establish the exact tumour type. Histopathological and molecular examination of tissue obtained through biopsy or surgical resection can provide definitive classification when clinically appropriate.
Treatment depends on tumour type, grade, molecular profile, location, size, symptoms, resectability, age and general health. Surgery can provide tissue for diagnosis, reduce tumour burden or relieve pressure, but complete removal may be unsafe when a tumour lies near essential functional structures. Radiotherapy can target residual or unresectable disease, while chemotherapy or other systemic treatments are used for selected tumour types. Some tumours require active surveillance when the risks of immediate intervention outweigh likely benefits. Treatment can therefore involve neurosurgery, neuro-oncology, radiotherapy, neurology, rehabilitation and supportive services.
Brain Tumours create particular treatment challenges because the brain is highly organised and damage to small areas can affect movement, speech, vision, memory, personality or other functions. Tumour-related swelling and increased intracranial pressure can produce serious complications even when the tumour itself is not histologically aggressive. Treatment can also affect neurological function, creating a need for rehabilitation and long-term support. Seizure management, corticosteroids in appropriate circumstances, management of headaches and other symptom-control strategies may accompany tumour-directed treatment. The effects of location and treatment mean that quality of life and functional outcomes are important considerations alongside tumour control.
Metastatic brain tumours are cancers that have spread to the brain from another primary site rather than originating there. This distinction affects staging and treatment because the biology of the primary cancer and its systemic disease burden become central to management. Brain metastases can occur with several cancer types and may produce neurological symptoms or be detected during staging. Primary brain tumours generally do not behave like conventional cancers that spread through the body; their clinical impact can instead arise from local invasion, compression, disruption of neural function and increased intracranial pressure.
A common misconception is that all Brain Tumours are malignant or that a headache automatically suggests a tumour. Neither is correct. Another misconception is that tumour size alone determines severity; location, growth rate, molecular features and effects on brain function can be more important than size in particular circumstances. Prognosis varies widely across tumour types, and population statistics cannot reliably predict an individual outcome. Advances in molecular classification, targeted therapies, immunological approaches, precision radiotherapy, surgical navigation and clinical trials continue to change management. Brain tumour care therefore requires integration of neurological assessment, imaging, pathology, molecular science, surgery, oncology and rehabilitation.
